Platinum analogue combination chemotherapy: Cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors

Background. Cisplatin is one of the single drugs that has shown the best documented effect in treating patients with locally recurrent or metastatic urothelial cancer. To the authors' knowledge, the effect of the combination of different platinum analogues in treating transitional cell carcinoma has not been evaluated previously neither experimentally nor in clinical studies.

[1]  L. Sengeløv,et al.  Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract , 1994, Cancer.

[2]  N L Geller,et al.  Effect of relative cumulative dose-intensity on survival of patients with urothelial cancer treated with M-VAC. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Wallner,et al.  Treatment of brain metastases from bladder cancer. , 1993, The Journal of urology.

[4]  A. Ribas,et al.  Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin‐based chemotherapy , 1992, Cancer.

[5]  L. Norton,et al.  Chemotherapy for urothelial tract malignancies: breaking the deadlock. , 1992, Seminars in surgical oncology.

[6]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Prüger,et al.  Carboplatin, Methotrexate and Vinblastin (Carbo‐MV) for Advanced Urothelial Cancer A Phase II Trial , 1991, American journal of clinical oncology.

[8]  N. Geller,et al.  Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy , 1991, Cancer.

[9]  D. Trump,et al.  RANDOMIZED PHASE II EVALUATION OF CARBOPLATIN AND CHIP IN ADVANCED TRANSITIONAL CELL CARCINOMA OF THE UROTHELIUM , 1990 .

[10]  C. Logothetis,et al.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  N. Geller,et al.  Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.

[12]  S. Fosså,et al.  Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. , 1989, British journal of urology.

[13]  H. Hansen,et al.  High-dose platinum consisting of combined carboplatin and cisplatin in previously untreated ovarian cancer patients with residual disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Tannock,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience. , 1989, The Journal of urology.

[15]  T. Kigure,et al.  Effect of adrenergic agents on urethral pressure and urethral compliance measurements in dog proximal urethra. , 1989, The Journal of urology.

[16]  R. Kefford,et al.  A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  N. Geller,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.

[18]  H. Hansen,et al.  The cytotoxic activity of cisplatin, carboplatin and teniposide alone and combined determined on four human small cell lung cancer cell lines by the clonogenic assay. , 1988, European journal of cancer & clinical oncology.

[19]  E. Christensen.  Multivariate survival analysis using Cox's regression model , 1987, Hepatology.

[20]  J. Willson,et al.  Platinum analogue combination chemotherapy: cisplatin and carboplatin--a phase I trial with pharmacokinetic assessment of the effect of cisplatin administration on carboplatin excretion. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Yagoda.  Chemotherapy of urothelial tract tumors , 1987, Cancer.

[22]  S. Fosså,et al.  Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. , 1987, The Journal of urology.

[23]  M. Troner,et al.  Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial. , 1987, The Journal of urology.

[24]  R. Oliver,et al.  Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer. , 1986, British journal of urology.

[25]  F. Freiha,et al.  Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Carmichael,et al.  Cis-platin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract. , 1985, British journal of urology.

[27]  P. Elson,et al.  Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide, and DDP in disseminated transitional cell carcinomas of the urinary tract. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Soloway,et al.  A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. A national bladder cancer collaborative group a study , 1983, Cancer.

[29]  M. Soloway,et al.  Cis‐diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer , 1981, Cancer.

[30]  H. Herr.  Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer. , 1980, The Journal of urology.

[31]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[32]  H. von der Maase,et al.  A phase II study of cisplatin plus methotrexate with folinic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium. , 1993, European journal of cancer.

[33]  M. Igawa,et al.  Analyses of factors affecting the outcome of combination chemotherapy in patients with advanced bladder cancer. , 1991, European urology.

[34]  K. Sikora,et al.  New combination chemotherapy programme for bladder cancer. , 1989, British journal of urology.

[35]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .

[36]  D.,et al.  Regression Models and Life-Tables , 2022 .